Operation Warp Speed for rare diseases: CBER leader says pilot is coming soon

13 Feb 2023
endpts.com
VaccineGene Therapy
The next generation of Operation Warp Speed is coming soon, and this time it’s going to take aim at rare diseases, Peter Marks, the director of the FDA’s Center for Biologics Evaluation and Research, told attendees of the Biopharma Congress in Washington, DC on Monday. “We’re getting ready to pilot that program,” Marks said, making clear the goal is to help areas with high unmet needs. He said “it’s not unlikely in some of these rare disease situations that there will be hiccups” and if those FDA-sponsor conversations can occur in real time, they can resolve those issues more quickly. Marks stressed that he trusts his deputy Celia Witten to find new talent for the FDA’s retiring leadership as the agency transitions from its Office of Tissues and Advanced Therapies to the super-office to be known as the Office of Therapeutic Products, or OTP. He also explained how he’s looking into using a Project Orbis-like approach to expanding the approval of gene and cell therapies throughout other high-income countries (e.g. UK, Japan, EU) as the FDA’s Oncology Center of Excellence currently does for some new cancer drugs and indications. “And we want to take it one step further for these rare diseases. For vaccines, there’s WHO-prequalification, which is basically, WHO says this vaccine has been licensed in a reference country, it’s good enough for us, it should be good enough for you, and the idea is to quickly do that for gene therapy so lower-income countries could potentially make use of these approvals. Why is that important? For some gene therapies, the only way people will get treatment is if they get gene therapy because those countries cannot afford supportive care, for instance,” Marks said, noting that “there may be ways to deal” with some of the massive upfront costs. When asked why there has been an increase in clinical holds from CBER, Marks noted multiple causes including an increase in clinical trials, less experienced sponsors in this cell and gene therapy space, and OTP is looking to bring on about 125 new staffers to help with the cell and gene therapy reviews thanks to the latest iteration of the user fee deals, but the market for talent is fiercely competitive. FDA’s outgoing OTAT director Wilson Bryan recently announced his intent to retire but told Endpoints News on Monday that he’s looking forward to the next challenge, and wanted to hand off the reins of the office to the next set of incoming leadership as the transition happens. Looking ahead, Bryan expressed candid fears that the agency may not end up pulling cell or gene therapies quickly when approved under the accelerated pathway, and even when there might be not enough evidence of efficacy from the confirmatory trial. He said he does think the accelerated pathway, which has only been used once so far for a cell/gene therapy, will be frequently used and that the confirmatory studies could take years to confirm benefit, especially if it’s a slowly developing disease. “We’re going to get into trouble with accelerated approval for gene therapies if it takes years to tell us if something works,” Bryan said. “Because then that means it takes years to tell us if it doesn’t work.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.